Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 1;20(3):240043.
doi: 10.1183/20734735.0043-2024. eCollection 2024 Oct.

Pulmonary complications of bone marrow transplantation

Affiliations
Review

Pulmonary complications of bone marrow transplantation

Helen O'Brien et al. Breathe (Sheff). .

Abstract

Bone marrow transplantation, now often known as haematopoietic stem cell transplantation (HSCT), is a complex choreographed procedure used to treat both acquired and inherited disorders of the bone marrow. It has proven invaluable as therapy for haematological and immunological disorders, and more recently in the treatment of metabolic and enzyme disorders. As the number of performed transplants grows annually, and with patients enjoying improved survival, a knowledge of both early and late complications of HSCT is essential for respiratory trainees and physicians in practice. This article highlights the spectrum of respiratory complications, both infectious and non-infectious, the timeline of their likely occurrence, and the approaches used for diagnosis and treatment, keeping in mind that more than one entity may occur simultaneously. As respiratory issues are often a leading cause of short- and long-term morbidity, consideration of a combined haematology/respiratory clinic may prove useful in this patient population.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: H. O'Brien, J. Murray and R.J. Fahy have no conflicts to disclose. N. Orfali reports consulting fees from Abbvie, Astellas, BMS, Servier, Takeda and Jazz; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Abbvie; and support for attending meetings and/or travel from Abbvie, Jazz, Pfizer, Servier and Takeda. In addition, N. Orfali is a member of the NCCP myeloid clinical advisory committee and is a board member of the Irish Blood Transfusion Service.

Figures

FIGURE 1
FIGURE 1
Timeline of pulmonary complications following haematopoietic stem cell transplantation. GvHD: graft-versus-host disease; PERDS: peri-engraftment respiratory distress syndrome; TRALI: transfusion-related acute lung injury; DAH: diffuse alveolar haemorrhage; PTLD: post-transplant lymphoproliferative disorder; EBV: Epstein–Barr virus; ALS: air leak syndrome; PVOD: pulmonary veno-occlusive disease; IIP: idiopathic interstitial pneumonia; PPFE: pleuroparenchymal fibroelastosis; RSV: respiratory syncytial virus. Adapted from [13].
FIGURE 2
FIGURE 2
Idiopathic pneumonia syndrome developing 80 days post-allogeneic haematopoietic stem cell transplantation, characterised by diffuse bilateral pulmonary infiltrates.
FIGURE 3
FIGURE 3
Cryptogenic organising pneumonia in a patient 112 days post-allogeneic haematopoietic stem cell transplantation, with patchy bilateral consolidation.
FIGURE 4
FIGURE 4
Bronchiolitis obliterans in a 31-year-old female with progressive dyspnoea over 8 weeks, 14 months after allogeneic haematopoietic stem cell transplantation. Small airway narrowing leads to mosaic perfusion on computed tomography of the thorax.
FIGURE 5
FIGURE 5
Pleuroparenchymal fibroelastosis (biopsy confirmed) in a 55-year-old male with chronic graft-versus-host disease. This is characterised by the development of apical pleural thickening, subpleural fibrosis, traction bronchiectasis, hilar retraction and, frequently, pneumothorax.
FIGURE 6
FIGURE 6
Invasive pulmonary aspergillosis. A cavitary pulmonary nodule, an area of consolidation with a “halo” sign and small peripheral peribronchial nodular infiltrates.

Similar articles

References

    1. Thomas ED, Buckner CD, Banaji M, et al. . One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511–533. doi:10.1182/blood.V49.4.511.511 - DOI - PubMed
    1. Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330: 827–838. doi:10.1056/NEJM199403243301206 - DOI - PubMed
    1. Passweg JR, Baldomero H, Ciceri F, et al. . Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A report from the EBMT Activity Survey. Bone Marrow Transplant 2023; 58: 647–658. doi:10.1038/s41409-023-01943-3 - DOI - PMC - PubMed
    1. D'Souza A, Fretham C, Lee SJ, et al. . Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant 2020; 26: e177–e182. doi:10.1016/j.bbmt.2020.04.013 - DOI - PMC - PubMed
    1. Snowden JA, Sanchez-Ortega I, Corbacioglu S, et al. . Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant 2022; 57: 1217–1239. doi:10.1038/s41409-022-01691-w - DOI - PMC - PubMed

LinkOut - more resources